OncoSec Medical To Present at Four Events in June
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at four events in June. The company’s agenda includes a number of high-profile scientific and investment conferences, coming on the heels of their presentation of new clinical data at the 2014 ASCO Annual Meeting. OncoSec’s June meeting itinerary is as follows:
Boston Biotech Boston CEO
Punit Dhillon, President and CEO, will take part in a panel discussion titled, “Alternative Business Models in Biotech”, at the Boston Biotech Boston CEO Conference on June 5, 2014 at 11:45 pm EST, at the Four Seasons Hotel in Boston, MA.
The Boston CEO Conference serves as a networking forum for industry CEOs, venture capital and private equity leaders, and key decision makers in the life sciences sector. Attendees gain valuable insights from presentations and panel discussions featuring CEOs from the world’s leading biopharmaceutical companies. Boston Biotech hosts exclusive thought-leader forums for senior bio-pharma executives. Each conference is highly interactive and meant to facilitate discussion, information sharing, networking, and corporate development among healthcare industry leaders. For more information, please visit: http://bbbiotechconference.com/conference-details.php?id=11
LD Micro 4th Invitational
Robert Pierce, M.D., Chief Medical Officer, will present a corporate overview of the company at the LD Micro 4th Invitational Conference, on June 4, 2014 at 1:00 pm PST, at the Luxe Hotel in Los Angeles, CA.
LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The 4th Invitational will feature company presentations and facilitate 1-on-1 meetings between business leaders and investors, as part of LD Micro’s ultimate goal of bringing out the finest ideas in micro-cap and showcasing them to a tight-knit and loyal investor base. For more information, please visit: http://www.ldmicro.com
2014 BIO International Convention
Robert Pierce, M.D., Chief Medical Officer, will present an overview of the company at the 2014 BIO International Convention, as part of the BIO Business Forum, taking place June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention is the largest venue for private company-to-company meetings in the world. According to an independent survey, partnering events such as BIO drive the majority of successful deals in the biopharma industry. This year’s exhibition will feature more than 1700 exhibitors and host thousands of organizations including leading biotech companies, top 25 pharma companies, top 20 CROs and CMOs, more than 300 academic institutions including major research labs and government agencies and the leading consultants and service companies. For more information, please visit: http://convention.bio.org/2014/
4th European Post-Chicago Melanoma/Skin Cancer Meeting
OncoSec representatives will attend and present at the 4th European Post-Chicago Melanoma/Skin Cancer Meeting, hosted by the European Association of Dermato Oncology (EADO). The meeting will take place June 26-27, 2014 at the Leonardo Royal Hotel in Munich, Germany.
The aim of the Interdisciplinary Global Conference on News in Melanoma/Skin Cancer, which highlights results and interpretations of ASCO 2014 presentations, is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies. EADO invites international key opinion leaders on melanoma, non-melanoma skin cancers and cutaneous lymphomas to this interactive meeting to give a comprehensive overview of new developments in melanoma and other skin cancers. This high-profile event allows the world’s leading experts in these fields to directly communicate with attendees through specified presentations and discussions on the latest clinical trial results and exciting new therapeutics. For more information, please visit: http://www.melanomaglobal2014.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma respectively (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination-based approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
OncoSec Medical Inc.
Veronica Vallejo, CFO, 855-662-6732
Source: OncoSec Medical Inc.
Released May 27, 2014